Works matching DE "OLAPARIB"

Results: 205

Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02048-7

By:

Wang, Zehua;
Pu, Tao;
Miao, Weiwei;
Gao, Yi;
Gao, Jianwen;
Zhang, Xinyan

Publication type:

Article

Pre-activation of autophagy impacts response to olaparib in prostate cancer cells.

Published in:

Communications Biology, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s42003-022-03210-5

By:

Cahuzac, Maxime;
Langlois, Patricia;
Péant, Benjamin;
Fleury, Hubert;
Mes-Masson, Anne-Marie;
Saad, Fred

Publication type:

Article

Successful management of metastatic ovarian carcinosarcoma with olaparib plus bevacizumab: a case report.

Published in:

European Journal of Gynaecological Oncology, 2022, v. 43, n. 3, p. 147, doi. 10.22514/ejgo.2022.002

By:

Takuya Yokoe;
Masato Kita;
Gen-ichiro Sumi;
Hiroshi Shiraga;
Hidetaka Okada

Publication type:

Article

Efficacy and safety of olaparib in the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review and meta-analysis.

Published in:

European Journal of Gynaecological Oncology, 2022, v. 43, n. 3, p. 46, doi. 10.22514/ejgo.2022.010

By:

Yan Wang;
Yan Cai;
Qiming Wang

Publication type:

Article

New treatment strategy for ovarian cancer with a BRCA gene mutation.

Published in:

European Journal of Gynaecological Oncology, 2021, v. 42, n. 1, p. 1, doi. 10.31083/j.ejgo.2021.01.2251

By:

Tadahiro Shoji;
Kotoka Kikuchi;
Hayato Kogita;
Nanako Jonai;
Hidetoshi Tomabechi;
Akiko Kudoh;
Eriko Takatori;
Takayuki Nagasawa;
Masahiro Kagabu;
Tsukasa Baba

Publication type:

Article

Genomic profiling in gynaecological oncology: the future is now!

Published in:

European Journal of Gynaecological Oncology, 2020, v. 41, n. 3, p. 323, doi. 10.31083/j.ejgo.2020.03.5363

By:

Roncati, Luca;
Vadalà, Maria;
Valentina, Pepe;
Corazzari, Veronica;
Palmieri, Beniamino

Publication type:

Article

ReOL -- OLaparib in the REal World. A retrospective observational study to evaluate the impact of olaparib on the real-world treatment of BRCA carrier patients with recurrent ovarian cancer.

Published in:

European Journal of Gynaecological Oncology, 2019, v. 40, n. 5, p. 759, doi. 10.12892/ejgo5165.2019

By:

De Matteis, E.;
Cormio, G.;
Naglieri, E.;
Scavelli, C.;
Loizzi, V.;
Cito, P.;
Chetrì, M. C.;
Tarantino, P.;
Mazzoni, E.;
Ronzino, G.

Publication type:

Article

Metastatic breast cancer with double heterozygosity for the BRCA1 and BRCA2 genes responding to olaparib: A case report.

Published in:

2024

By:

Shao, Bin;
Di, Lijun

Publication type:

Case Study

Olaparib: First Global Approval.

Published in:

2015

By:

Deeks, Emma

Publication type:

Journal Article

Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib.

Published in:

OncoTargets & Therapy, 2023, v. 16, p. 1061, doi. 10.2147/OTT.S426923

By:

Zhang, Anqing;
Zhang, Liqin;
Xie, Xia;
Liu, Dan

Publication type:

Article

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.

Published in:

2022

By:

Zhao, Yingchao;
Jiang, Yao

Publication type:

Case Study

Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 5353, doi. 10.2147/OTT.S334847

By:

Jia, Xiaomeng;
Zhao, Shanshan;
Li, Xiang;
Lv, Li;
Chen, Xin;
Pan, Evenki;
Ou, Qiuxiang;
Song, Chen;
Sun, Siwen;
Zhao, Jinbo;
Xu, Lingzhi;
Li, Man

Publication type:

Article

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum].

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 5167, doi. 10.2147/ott.s315170

By:

LeVee, Alexis;
Lin, Ching Ying;
Posadas, Edwin;
Figlin, Robert;
Bhowmick, Neil A;
Vizio, Dolores Di;
Ellis, Leigh;
Rosser, Charlos J;
Freeman, Michael R;
Theodorescu, Dan;
Freedland, Stephen J;
Gong, Jun

Publication type:

Article

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 4819, doi. 10.2147/OTT.S315170

By:

LeVee, Alexis;
Lin, Ching Ying;
Posadas, Edwin;
Figlin, Robert;
Bhowmick, Neil A;
Vizio, Dolores Di;
Ellis, Leigh;
Rosser, Charlos J;
Freeman, Michael R;
Theodorescu, Dan;
Freedland, Stephen J;
Gong, Jun

Publication type:

Article

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 4383, doi. 10.2147/OTT.S291267

By:

Wang, Zhenwei;
Dai, Zhihong;
Wang, Bingwei;
Gao, Yuren;
Gao, Xiang;
Wang, Liang;
Zhou, Sihai;
Yang, Liqin;
Qiu, Xiaofu;
Liu, Zhiyu

Publication type:

Article

Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation.

Published in:

OncoTargets & Therapy, 2021, v. 14, p. 3895, doi. 10.2147/OTT.S317514

By:

Su, Yu-Li;
Ng, Ca Tung;
Jan, Yi-Hua;
Hsieh, Yi-Lin;
Wu, Chia-Ling;
Tan, Kien Thiam

Publication type:

Article

Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer.

Published in:

Clinical Genitourinary Cancer, 2023, v. 21, n. 1, p. 183, doi. 10.1016/j.clgc.2022.07.005

By:

Nindra, Udit;
Jun Hee Hong;
Balakrishnar, Bavanthi;
Pal, Abhijit;
Wei Chua

Publication type:

Article

Combinatorial Effects of Cisplatin and PARP Inhibitor Olaparib on Survival, Intestinal Integrity, and Microbiome Modulation in Murine Model.

Published in:

International Journal of Molecular Sciences, 2025, v. 26, n. 3, p. 1191, doi. 10.3390/ijms26031191

By:

Matsumura, Mitsuki;
Fujihara, Hisako;
Maita, Kanna;
Miyakawa, Moeko;
Sakai, Yushi;
Nakayama, Ryoko;
Ito, Yumi;
Hasebe, Mitsuhiko;
Kawaguchi, Koji;
Hamada, Yoshiki

Publication type:

Article

Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.

Published in:

International Journal of Molecular Sciences, 2024, v. 25, n. 24, p. 13549, doi. 10.3390/ijms252413549

By:

Kekeeva, Tatiana;
Dudina, Irina;
Andreeva, Yulia;
Tanas, Alexander;
Kalinkin, Alexey;
Musatova, Victoria;
Chernorubashkina, Natalia;
Khokhlova, Svetlana;
Tikhomirova, Tatiana;
Volkonsky, Mikhail;
Kutsev, Sergey;
Zaletaev, Dmitry;
Strelnikov, Vladimir

Publication type:

Article

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

Published in:

BMC Cancer, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12885-015-1090-7

By:

Na Young Jang;
Dan Hyo Kim;
Bong Jun Cho;
Eun Jung Choi;
Jong-Soo Lee;
Hong-Gyun Wu;
Eui Kyu Chie;
In Ah Kim

Publication type:

Article

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.

Published in:

BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-813

By:

Choy, Edwin;
Butrynski, James E.;
Harmon, David C.;
Morgan, Jeffrey A.;
George, Suzanne;
Wagner, Andrew J.;
D'Adamo, David;
Cote, Gregory M.;
Flamand, Yael;
Benes, Cyril H.;
Haber, Daniel A.;
Baselga, Jose M.;
Demetri, George D.

Publication type:

Article

Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer.

Published in:

Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 11, p. 8681, doi. 10.1007/s00432-023-04811-1

By:

Yue, Wang;
Yupeng, Gu;
Jun, Cao;
Kui, Jiang

Publication type:

Article

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.

Published in:

Drugs - Real World Outcomes, 2023, v. 10, n. 2, p. 207, doi. 10.1007/s40801-022-00349-9

By:

Bellier, Charlotte;
Gladieff, Laurence;
Le Du, Fanny;
Berton, Dominique;
Bonnard, Charlotte;
Suau, Delphine;
Richard, Anne-Céline;
Brenner, Ophélie;
Lahouegue, Amir;
Freyer, Gilles;
Floquet, Anne;
Frank, Sophie;
Kfoury, Maria

Publication type:

Article

Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple‐negative breast cancer.

Published in:

2024

By:

Shen, Xia‐Bo;
Wu, Jia‐Yi;
Li, Jia‐ying;
Shao, Xi‐Ying;
Wang, Xiao‐Jia

Publication type:

Case Study

BRCA2 reversion mutation confers resistance to olaparib in breast cancer.

Published in:

2023

By:

Yamamoto, Shinya;
Kawashima, Kei;
Fujiwara, Yoshie;
Adachi, Shoko;
Narui, Kazutaka;
Hosaka, Chiaki;
Takahashi, Rina;
Tsuyuki, Sho;
Sugimori, Makoto;
Tanoshima, Miki;
Sasamoto, Mahato;
Oshi, Masanori;
Yamada, Akimitsu;
Kunisaki, Chikara;
Endo, Itaru

Publication type:

Case Study

Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.

Published in:

2022

By:

Lelong, Margaux;
Raoul, Jean‐Luc;
Touchefeu, Yann;
Berthelot, Jean‐Marie;
Arnolfo, Paul;
Matysiak‐Budnik, Tamara;
Senellart, Hélène

Publication type:

Case Study

Metastatic non-small cell lung cancer with BRCA2 mutation—a therapeutic challenge.

Published in:

Oxford Medical Case Reports, 2025, v. 2025, n. 4, p. 1, doi. 10.1093/omcr/omaf009

By:

Naviwala, Saad Salim;
Khan, Waqas Ahmed;
Shoaib, Daania;
Nafees, Taha;
Shakeel, Muzammil;
Rashid, Yasmin Abdul

Publication type:

Article

Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome.

Published in:

Oxford Medical Case Reports, 2022, v. 2022, n. 11, p. 1, doi. 10.1093/omcr/omac124

By:

Tsuneizumi, Michiko;
Terada, Shuzo;
Usui, Takeshi;
Yamaguchi, Kei;
Hayami, Ryosuke;
Matsunuma, Ryoichi

Publication type:

Article

Inhibition of Colorectal Cancer Cell Survival by Paclitaxel Combined with Olaparib.

Published in:

Adiyaman University Journal of Science & Technology / Adıyaman Üniversitesi Fen Bilimleri Dergisi, 2020, v. 10, n. 2, p. 427, doi. 10.37094/adyujsci.737262

By:

GÜNDOĞDU, Ramazan

Publication type:

Article

Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study.

Published in:

Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-14197-8

By:

Savarese, Teresa;
Abate, Andrea;
Basnet, Ram Manohar;
Lorini, Luigi;
Gurizzan, Cristina;
Tomasoni, Michele;
Lombardi, Davide;
Tomasini, Davide;
Zizioli, Daniela;
Memo, Maurizio;
Berruti, Alfredo;
Bonini, Sara A.;
Sigala, Sandra;
Bossi, Paolo

Publication type:

Article

BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models.

Published in:

Frontiers in Pharmacology, 2024, p. 01, doi. 10.3389/fphar.2024.1390116

By:

Guffanti, Federica;
Mengoli, Ilaria;
Alvisi, Maria Francesca;
Dellavedova, Giulia;
Giavazzi, Raffaella;
Fruscio, Robert;
Rulli, Eliana;
Damia, Giovanna

Publication type:

Article

Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.

Published in:

Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-023-01615-6

By:

Mani, Chinnadurai;
Acharya, Ganesh;
Saamarthy, Karunakar;
Ochola, Damieanus;
Mereddy, Srinidhi;
Pruitt, Kevin;
Manne, Upender;
Palle, Komaraiah

Publication type:

Article

Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature.

Published in:

BMC Pulmonary Medicine, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12890-023-02569-3

By:

Ishimoto, Hiroshi;
Sakamoto, Noriho;
Kido, Takashi;
Ozasa, Mutsumi;
Tsutsui, Shin;
Mori, Mayako;
Setoguchi, Daichi;
Takemoto, Shinnosuke;
Obase, Yasushi;
Ishimatsu, Yuji;
Tomonaga, Chiharu;
Matsumoto, Kanako;
Morisaki, Sachiko;
Miura, Kiyonori;
Mukae, Hiroshi

Publication type:

Article

Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.

Published in:

BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03409-9

By:

Li, Huayi;
Peng, Zikun;
Zhu, Jianqing;
Zhao, Weidong;
Huang, Yi;
An, Ruifang;
Zheng, Hong;
Qu, Pengpeng;
Wang, Li;
Zhou, Qi;
Wang, Danbo;
Lou, Ge;
Wang, Jing;
Wang, Ke;
Kong, Beihua;
Xie, Xing;
Yin, Rutie;
Low, John;
Rozita, Abdul Malik;
Sen, Lim Chun

Publication type:

Article

Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction: A Case Report.

Published in:

2024

By:

YUTA ENDO;
NORIHITO KAMO;
ASAMI KATO;
TETSU SATO;
CHIKAKO OKABE;
SHIGENORI FURUKAWA;
TAKAFUMI WATANABE;
SHU SOEDA

Publication type:

Case Study

The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model.

Published in:

In Vivo, 2021, v. 35, n. 4, p. 2015, doi. 10.21873/invivo.12470

By:

KIHWAN HWANG;
JIN-HAN LEE;
SANG HO KIM;
KYEONG-O GO;
SO YOUNG JI;
JUNG HO HAN;
CHAE-YONG KIM

Publication type:

Article

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells.

Published in:

Experimental & Therapeutic Medicine, 2021, v. 22, n. 3, p. N.PAG, doi. 10.3892/etm.2021.10367

By:

Gao, Jianwen;
Wang, Zehua;
Fu, Jiayu;
A., Jisaihan;
Ohno, Yuko;
Xu, Congjian

Publication type:

Article

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.

Published in:

Cancer Biology & Medicine, 2022, v. 19, n. 8, p. 1150, doi. 10.20892/j.issn.2095-3941.2021.0178

By:

Yangyang Kong;
Chang Xu;
Xiaohui Sun;
Hao Sun;
Xiaotong Zhao;
Ningning He;
Kaihua Ji;
Qin Wang;
Liqing Du;
Jinhan Wang;
Manman Zhang;
Yang Liu;
Yan Wang;
Qiang Liu

Publication type:

Article

Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-43258-9

By:

Gao, Dongmei;
Wang, Guopeng;
Wu, Honghai;
Ren, Jiawei

Publication type:

Article

CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-45964-w

By:

Witz, Andréa;
Dardare, Julie;
Francois, Aurélie;
Husson, Marie;
Rouyer, Marie;
Demange, Jessica;
Merlin, Jean-Louis;
Gilson, Pauline;
Harlé, Alexandre

Publication type:

Article

Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-43258-9

By:

Gao, Dongmei;
Wang, Guopeng;
Wu, Honghai;
Ren, Jiawei

Publication type:

Article

Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-39224-0

By:

Tashiro, Ryota;
Kawazoe, Hitoshi;
Mamishin, Kanako;
Seto, Keisuke;
Udagawa, Ryoko;
Saito, Yoshimasa;
Hashimoto, Hironobu;
Shimoi, Tatsunori;
Yonemori, Kan;
Yonemura, Masahito;
Terakado, Hiroyuki;
Nishimura, Takahiro;
Kawasaki, Toshikatsu;
Furukawa, Tetsuya;
Nakamura, Tomonori

Publication type:

Article

Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-38760-z

By:

Schettini, Francesco;
De Bonis, Maria Valeria;
Strina, Carla;
Milani, Manuela;
Ziglioli, Nicoletta;
Aguggini, Sergio;
Ciliberto, Ignazio;
Azzini, Carlo;
Barbieri, Giuseppina;
Cervoni, Valeria;
Cappelletti, Maria Rosa;
Ferrero, Giuseppina;
Ungari, Marco;
Locci, Mariavittoria;
Paris, Ida;
Scambia, Giovanni;
Ruocco, Gianpaolo;
Generali, Daniele

Publication type:

Article

PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib.

Published in:

Clinical & Translational Medicine, 2024, v. 14, n. 12, p. 1, doi. 10.1002/ctm2.70111

By:

Lei, Xin‐Yuan;
He, Kai‐Yue;
Li, Qiu‐Tong;
Zhang, Lei;
Wu, Dan‐Hui;
Yang, Jing‐Yu;
Guo, Jin‐Rong;
Liu, Meng‐Jie;
Zhao, Zi‐Long;
Li, Jun‐Qi;
Liu, Huai;
Zhao, Yuan;
Li, Yu‐Jia;
Sun, Qian‐Hui;
Wu, Chen‐Guang;
Wang, Yun‐Fan;
Cao, Geng‐Sheng;
Wang, Gang;
Jian, Yong‐Ping;
Xu, Zhi‐Xiang

Publication type:

Article

Body composition and inflammation variables as the potential prognostic factors in epithelial ovarian cancer treated with Olaparib.

Published in:

Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2024.1359635

By:

Xingzi Guo;
Jie Tang;
Haifeng He;
Lian Jian;
Ouyang Qiang;
Yongzhi Xie

Publication type:

Article

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway.

Published in:

Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1302850

By:

Yasushi Iida;
Nozomu Yanaihara;
Yuki Yoshino;
Misato Saito;
Ryosuke Saito;
Junya Tabata;
Ayako Kawabata;
Masataka Takenaka;
Natsuko Chiba;
Aikou Okamoto

Publication type:

Article

Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice.

Published in:

Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1304303

By:

Romero, Ignacio;
Guerra, Eva;
Madariaga, Ainhoa;
Manso, Luis

Publication type:

Article

Successful Extended At-Home Olaparib Desensitization After a Hypersensitivity Reaction: A Case Report.

Published in:

Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 3, p. 153

By:

Jia, Lily Y.;
Sendrowski, Brendan;
Lax, Timothy;
Shea, Meghan

Publication type:

Article

Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.

Published in:

Journal of Gynecologic Oncology, 2024, v. 35, n. 1, p. 1, doi. 10.3802/jgo.2024.35.e2

By:

Youwen Zhu;
Qiuping Yang;
Kun Liu;
Hui Cao;
Hong Zhu

Publication type:

Article

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).

Published in:

Journal of Gynecologic Oncology, 2021, v. 32, n. 6, p. 1, doi. 10.3802/jgo.2021.32.e90

By:

Se Ik Kim;
Jeong-Won Lee;
Kidong Kim;
Lee, Maria;
Jigeun Yoo;
Min Chul Choi;
Suhyun Hwangbo;
Young Hwa Kwak;
Jong-Min Lee;
So-Jin Shin;
Seung-Hyuk Shim;
Min Kyu Kim

Publication type:

Article